NO329314B1 - Krystallmodifikasjon av et farmasoytisk middel, anvendelse derav samt farmasoytisk preparat inneholdende krystallmodifikasjonen. - Google Patents
Krystallmodifikasjon av et farmasoytisk middel, anvendelse derav samt farmasoytisk preparat inneholdende krystallmodifikasjonen. Download PDFInfo
- Publication number
- NO329314B1 NO329314B1 NO19983666A NO983666A NO329314B1 NO 329314 B1 NO329314 B1 NO 329314B1 NO 19983666 A NO19983666 A NO 19983666A NO 983666 A NO983666 A NO 983666A NO 329314 B1 NO329314 B1 NO 329314B1
- Authority
- NO
- Norway
- Prior art keywords
- weak
- medium
- modification
- crystal modification
- strong
- Prior art date
Links
- 238000012986 modification Methods 0.000 title claims description 88
- 230000004048 modification Effects 0.000 title claims description 88
- 239000013078 crystal Substances 0.000 title claims description 26
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 238000001228 spectrum Methods 0.000 claims description 9
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 8
- 230000005540 biological transmission Effects 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- 238000001757 thermogravimetry curve Methods 0.000 claims description 6
- 230000009102 absorption Effects 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 238000005079 FT-Raman Methods 0.000 claims description 4
- 238000001028 reflection method Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OPJHWTKDQYKYHL-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1CC1=C(F)C=CC=C1F OPJHWTKDQYKYHL-UHFFFAOYSA-N 0.000 description 1
- JSZUBPHMRHROHZ-UHFFFAOYSA-N 2-(azidomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CN=[N+]=[N-] JSZUBPHMRHROHZ-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000004279 X-ray Guinier Methods 0.000 description 1
- 238000005147 X-ray Weissenberg Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH140497 | 1997-06-10 | ||
PCT/EP1998/003428 WO1998056773A1 (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Publications (3)
Publication Number | Publication Date |
---|---|
NO983666D0 NO983666D0 (no) | 1998-08-11 |
NO983666L NO983666L (no) | 1998-12-17 |
NO329314B1 true NO329314B1 (no) | 2010-09-27 |
Family
ID=4209650
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19983667A NO329315B1 (no) | 1997-06-10 | 1998-08-11 | Krystallmodifikasjon av forbindelse, farmasoytiske preparater inneholdende denne og anvendelse av krystallmodifikasjonen. |
NO19983666A NO329314B1 (no) | 1997-06-10 | 1998-08-11 | Krystallmodifikasjon av et farmasoytisk middel, anvendelse derav samt farmasoytisk preparat inneholdende krystallmodifikasjonen. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19983667A NO329315B1 (no) | 1997-06-10 | 1998-08-11 | Krystallmodifikasjon av forbindelse, farmasoytiske preparater inneholdende denne og anvendelse av krystallmodifikasjonen. |
Country Status (37)
Country | Link |
---|---|
US (6) | US6740669B1 (zh) |
EP (2) | EP0994864B1 (zh) |
JP (2) | JP3672574B2 (zh) |
KR (2) | KR100409168B1 (zh) |
CN (3) | CN1132820C (zh) |
AR (4) | AR012945A1 (zh) |
AT (2) | ATE232852T1 (zh) |
AU (2) | AU725517B2 (zh) |
BR (2) | BR9804947A (zh) |
CA (3) | CA2256013C (zh) |
CO (2) | CO4940452A1 (zh) |
CY (1) | CY2007014I2 (zh) |
CZ (2) | CZ292481B6 (zh) |
DE (3) | DE69811500T2 (zh) |
DK (2) | DK0994863T3 (zh) |
ES (2) | ES2197485T3 (zh) |
FR (1) | FR07C0037I2 (zh) |
HK (3) | HK1028242A1 (zh) |
HU (2) | HU226107B1 (zh) |
ID (2) | ID27660A (zh) |
IL (2) | IL125732A (zh) |
LU (1) | LU91345I2 (zh) |
MY (2) | MY120156A (zh) |
NL (1) | NL300284I2 (zh) |
NO (2) | NO329315B1 (zh) |
NZ (2) | NZ331371A (zh) |
PE (2) | PE79799A1 (zh) |
PL (2) | PL191943B1 (zh) |
PT (1) | PT994864E (zh) |
RU (2) | RU2198167C2 (zh) |
SI (2) | SI0994863T1 (zh) |
SK (2) | SK283734B6 (zh) |
TR (2) | TR199801631T1 (zh) |
TW (2) | TW403740B (zh) |
UY (1) | UY25844A1 (zh) |
WO (2) | WO1998056772A1 (zh) |
ZA (2) | ZA984966B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
ES2299720T3 (es) * | 2002-05-31 | 2008-06-01 | Schering Corporation | Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v. |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
US20090069390A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched rufinamide |
JP2012505191A (ja) * | 2008-10-13 | 2012-03-01 | シプラ・リミテッド | ルフィナマイドの製造方法 |
CN101768124B (zh) * | 2008-12-30 | 2012-01-04 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
IT1395736B1 (it) * | 2009-08-04 | 2012-10-19 | Dipharma Francis Srl | Forme cristalline di rufinamide |
EP2473051B1 (en) * | 2009-09-04 | 2016-02-10 | Tactical Therapeutics, Inc. | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
US8884026B2 (en) | 2010-04-30 | 2014-11-11 | Laboratorios Lesvi, S.L. | Process for preparing rufinamide intermediate |
EP2465853A1 (en) * | 2010-12-14 | 2012-06-20 | Laboratorios Lesvi, S.L. | Polymorph of rufinamide and process for obtaining it |
ITMI20110718A1 (it) | 2011-04-29 | 2012-10-30 | Dipharma Francis Srl | Procedimento per la purificazione di rufinamide |
US10206874B2 (en) | 2012-07-20 | 2019-02-19 | Hetero Research Foundation | Rufinamide solid dispersion |
WO2021099481A1 (en) | 2019-11-20 | 2021-05-27 | Medichem, S.A. | Solid composition containing rufinamide |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992378A (en) | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
GB1511195A (en) | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4346097A (en) * | 1980-09-30 | 1982-08-24 | Warner-Lambert Company | Method for treating convulsions with pyrazole-4-carboxamide derivatives |
FI834666A (fi) | 1982-12-23 | 1984-06-24 | Ciba Geigy Ag | Foerfarande foer framstaellning av nya aralkyltriazolfoereningar. |
US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
US4511572A (en) * | 1983-03-18 | 1985-04-16 | The University Of Kentucky Research Foundation | Triazoline anticonvulsant drugs |
FI93544C (fi) * | 1985-04-18 | 1995-04-25 | Ciba Geigy Ag | Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi |
CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
JPH02214504A (ja) | 1989-02-15 | 1990-08-27 | Nissan Chem Ind Ltd | 光学活性キノキサリン化合物の晶析法 |
JPH04506967A (ja) | 1989-07-27 | 1992-12-03 | ジー.ディー.サール アンド カンパニー | 高血圧症治療用腎選択性生成物 |
IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
DK0556393T3 (da) | 1990-11-06 | 2000-10-16 | Yamanouchi Pharma Co Ltd | Tilkondenseret pyrazinderivat |
JP2753911B2 (ja) | 1991-12-06 | 1998-05-20 | キッセイ薬品工業株式会社 | N−tert−ブチル−1−メチル−3,3−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 |
DE4217952A1 (de) | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
GB9419318D0 (en) | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
DE69609314T2 (de) | 1995-02-22 | 2001-06-13 | Aventis Pharma Ltd | Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung |
CA2260065C (en) * | 1996-07-11 | 2006-10-17 | Novartis Ag | Process for preparing 1-substituted 4-cyano-1,2,3-triazoles |
TW403740B (en) | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
-
1998
- 1998-06-04 TW TW087108859A patent/TW403740B/zh not_active IP Right Cessation
- 1998-06-04 TW TW087108858A patent/TW526195B/zh not_active IP Right Cessation
- 1998-06-08 DE DE69811500T patent/DE69811500T2/de not_active Expired - Lifetime
- 1998-06-08 DE DE69813560T patent/DE69813560T2/de not_active Expired - Lifetime
- 1998-06-08 PE PE1998000478A patent/PE79799A1/es not_active IP Right Cessation
- 1998-06-08 CN CN988000113A patent/CN1132820C/zh not_active Expired - Lifetime
- 1998-06-08 IL IL12573298A patent/IL125732A/en not_active IP Right Cessation
- 1998-06-08 KR KR10-1998-0708149A patent/KR100409168B1/ko not_active IP Right Cessation
- 1998-06-08 CA CA002256013A patent/CA2256013C/en not_active Expired - Lifetime
- 1998-06-08 NZ NZ331371A patent/NZ331371A/xx not_active IP Right Cessation
- 1998-06-08 JP JP53628898A patent/JP3672574B2/ja not_active Expired - Lifetime
- 1998-06-08 AT AT98934929T patent/ATE232852T1/de active
- 1998-06-08 AU AU84372/98A patent/AU725517B2/en not_active Expired
- 1998-06-08 ES ES98934930T patent/ES2197485T3/es not_active Expired - Lifetime
- 1998-06-08 TR TR1998/01631T patent/TR199801631T1/xx unknown
- 1998-06-08 PL PL330764A patent/PL191943B1/pl unknown
- 1998-06-08 DK DK98934929T patent/DK0994863T3/da active
- 1998-06-08 DE DE122007000051C patent/DE122007000051I2/de active Active
- 1998-06-08 US US09/125,329 patent/US6740669B1/en not_active Expired - Lifetime
- 1998-06-08 PL PL330798A patent/PL192114B1/pl unknown
- 1998-06-08 CZ CZ19982533A patent/CZ292481B6/cs not_active IP Right Cessation
- 1998-06-08 SI SI9830405T patent/SI0994863T1/xx unknown
- 1998-06-08 AU AU84371/98A patent/AU725528B2/en not_active Expired
- 1998-06-08 CA CA002256015A patent/CA2256015C/en not_active Expired - Lifetime
- 1998-06-08 CZ CZ19982534A patent/CZ292260B6/cs not_active IP Right Cessation
- 1998-06-08 JP JP53628998A patent/JP3672575B2/ja not_active Expired - Lifetime
- 1998-06-08 SI SI9830450T patent/SI0994864T1/xx unknown
- 1998-06-08 NZ NZ331370A patent/NZ331370A/xx not_active IP Right Cessation
- 1998-06-08 HU HU0000798A patent/HU226107B1/hu unknown
- 1998-06-08 TR TR1998/01630T patent/TR199801630T1/xx unknown
- 1998-06-08 ES ES98934929T patent/ES2192779T3/es not_active Expired - Lifetime
- 1998-06-08 WO PCT/EP1998/003427 patent/WO1998056772A1/en active IP Right Grant
- 1998-06-08 PT PT98934930T patent/PT994864E/pt unknown
- 1998-06-08 ID IDW980065D patent/ID27660A/id unknown
- 1998-06-08 SK SK1094-98A patent/SK283734B6/sk not_active IP Right Cessation
- 1998-06-08 CN CNB2004100473675A patent/CN1298708C/zh not_active Expired - Lifetime
- 1998-06-08 HU HU0002113A patent/HU225153B1/hu unknown
- 1998-06-08 RU RU99104300/04A patent/RU2198167C2/ru active
- 1998-06-08 BR BR9804947A patent/BR9804947A/pt not_active Application Discontinuation
- 1998-06-08 EP EP98934930A patent/EP0994864B1/en not_active Expired - Lifetime
- 1998-06-08 DK DK98934930T patent/DK0994864T3/da active
- 1998-06-08 CN CNB988056755A patent/CN1159300C/zh not_active Expired - Lifetime
- 1998-06-08 EP EP98934929A patent/EP0994863B1/en not_active Expired - Lifetime
- 1998-06-08 IL IL12573398A patent/IL125733A/en active Protection Beyond IP Right Term
- 1998-06-08 SK SK1093-98A patent/SK283685B6/sk not_active IP Right Cessation
- 1998-06-08 KR KR10-1998-0708150A patent/KR100425656B1/ko not_active IP Right Cessation
- 1998-06-08 PE PE1998000479A patent/PE80999A1/es not_active IP Right Cessation
- 1998-06-08 CA CA2614926A patent/CA2614926C/en not_active Expired - Lifetime
- 1998-06-08 AT AT98934930T patent/ATE237599T1/de active
- 1998-06-08 BR BR9804946A patent/BR9804946A/pt not_active Application Discontinuation
- 1998-06-08 RU RU99104299/04A patent/RU2194041C2/ru active
- 1998-06-08 WO PCT/EP1998/003428 patent/WO1998056773A1/en active IP Right Grant
- 1998-06-08 ID IDW980066D patent/ID21014A/id unknown
- 1998-06-09 CO CO98032879A patent/CO4940452A1/es unknown
- 1998-06-09 MY MYPI98002570A patent/MY120156A/en unknown
- 1998-06-09 ZA ZA984966A patent/ZA984966B/xx unknown
- 1998-06-09 ZA ZA984967A patent/ZA984967B/xx unknown
- 1998-06-09 MY MYPI98002572A patent/MY125854A/en unknown
- 1998-06-09 AR ARP980102707A patent/AR012945A1/es not_active Application Discontinuation
- 1998-06-09 CO CO98032885A patent/CO4940448A1/es unknown
- 1998-06-09 AR ARP980102708A patent/AR012946A1/es not_active Application Discontinuation
- 1998-08-11 NO NO19983667A patent/NO329315B1/no not_active IP Right Cessation
- 1998-08-11 NO NO19983666A patent/NO329314B1/no not_active IP Right Cessation
-
1999
- 1999-12-10 UY UY25844A patent/UY25844A1/es not_active Application Discontinuation
-
2000
- 2000-10-25 HK HK00106807A patent/HK1028242A1/xx not_active IP Right Cessation
- 2000-10-25 HK HK00106804A patent/HK1028241A1/xx not_active IP Right Cessation
- 2000-11-17 HK HK00107340A patent/HK1028031A1/xx not_active IP Right Cessation
-
2001
- 2001-05-31 US US09/871,366 patent/US6455556B2/en not_active Expired - Lifetime
-
2002
- 2002-11-14 US US10/294,408 patent/US20030125568A1/en not_active Abandoned
-
2004
- 2004-02-26 US US10/787,528 patent/US20040167186A1/en not_active Abandoned
-
2006
- 2006-01-11 US US11/329,945 patent/US7750028B2/en not_active Expired - Fee Related
-
2007
- 2007-05-17 AR ARP070102132A patent/AR061005A2/es not_active Application Discontinuation
- 2007-05-17 AR ARP070102131A patent/AR061004A2/es unknown
- 2007-07-03 NL NL300284C patent/NL300284I2/nl unknown
- 2007-07-04 LU LU91345C patent/LU91345I2/fr unknown
- 2007-07-06 FR FR07C0037C patent/FR07C0037I2/fr active Active
- 2007-07-13 CY CY200700014C patent/CY2007014I2/el unknown
-
2010
- 2010-04-26 US US12/767,003 patent/US8076362B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7750028B2 (en) | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide | |
MXPA98006950A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic | |
MXPA98006951A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |